BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Achillion Pharmaceuticals, Inc. 

300 George Street

New Haven  Connecticut  06511  U.S.A.
Phone: 203-624-7000 Fax: 203-624-7003


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical

Segment
Drug Discovery





 Company News
Achillion Pharmaceuticals, Inc. (ACHN) Added To The Russell 2000 And Russell Microcap Indexes 7/2/2014 7:10:58 AM
AbbVie (ABBV) And Johnson & Johnson (JNJ) Were In A Bidding War For Idenix Pharmaceuticals, Inc. (IDIX), Will Achillion Pharmaceuticals, Inc. (ACHN) Be The Next Target? 6/12/2014 5:38:38 AM
Achillion Pharmaceuticals, Inc. (ACHN) To Present At Two Upcoming Investor Conferences 6/11/2014 7:28:09 AM
Achillion Pharmaceuticals, Inc. (ACHN) Surges As The FDA Lifts Hold On Hepatitis C Trial; Stock Up +83.29% At Market Close (June 10, 2014) 6/10/2014 7:27:30 AM
Achillion Pharmaceuticals, Inc. (ACHN) Reports First Quarter 2014 Financial Results 5/7/2014 8:59:24 AM
Achillion Pharmaceuticals, Inc. (ACHN) To Present At Three Upcoming Investor Conferences 5/1/2014 9:18:25 AM
Achillion Pharmaceuticals, Inc. (ACHN) Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, For HCV 4/30/2014 4:01:47 PM
Achillion Pharmaceuticals, Inc. (ACHN) Announces Oral Presentations Given At APASL 2014 Detailing Clinical Activity Of ACH-3102, Second-Generation NS5A Inhibitor, Against Genotype 1b HCV 3/14/2014 9:33:41 AM
Achillion Pharmaceuticals, Inc. (ACHN) Reports 2013 Fourth Quarter And Year-End Financial Results 3/7/2014 8:37:34 AM
Achillion Pharmaceuticals, Inc. (ACHN) To Present At Two Upcoming Investor Conferences 2/10/2014 8:56:50 AM
12345678910...